LINC01116 Affects Patient Survival Differently and is Dissimilarly Expressed in ER+ and ER- Breast Cancer Samples

Overview

Journal Cancer Rep (Hoboken)

Specialty Oncology

Date 2023 Jun 15

PMID 37321964

Authors

Mohammadjavad Karimi Taheri

Sogol Ghanbari

Akram Gholipour

Taraneh Givi

Majid Sadeghizadeh

Affiliations

Soon will be listed here.

Abstract

Background: Breast cancer is the most commonly detected cancer and one of the leading causes of cancer mortality. Emerging evidence supports that aberrant expression of lncRNAs is correlated with tumor progression and various aspects of tumor development.

Aim: This study aimed to evaluate the expression pattern of LINC01116 in breast cancer tissues and investigate the impact of LINC01116 on patients' survival.

Methods And Results: Microarray and qRT-PCR data analysis were performed, and the KM-plotter database was used in this study. In addition, the gain of function approach was performed to examine the effect of LINC01116 on breast cancer cells in-vitro. The results exhibited that LINC01116 is meaningfully upregulated in the ER+ tumor specimens compared to the ER- ones. Also, relative to normal tissues, the expression of LINC01116 in ER+ and ER- tumor tissues significantly increased and decreased, respectively. ROC curve analysis revealed the power of LINC01116 in distinguishing ER+ from ER- samples. Additionally, the Kaplan-Meier survival analysis showed that the LINC01116 expression positively correlates with survival probability in all as well as ER+ patients. However, this correlation was negative in ER- patients. Furthermore, our results showed that the overexpression of LINC01116 induces TGF-β signaling in ER- cells (MDA-MB-231), and microarray data analysis revealed that LINC01116 is significantly upregulated in 17β-Estradiol treated MCF7 cells.

Conclusion: In conclusion, our results suggest that LINC01116 can be a potential biomarker in distinguishing ER+ and ER- tissues and has different effects on patients' survival based on ER status by affecting TGF-β and ER signaling.

Citing Articles

High linc01116 expression may contribute to a poor prognosis in various cancers based on systematic reviews and meta-analyses.

Fan S, Li D, Zhang Q, Xu L, Zeng T, Liu Q BMC Cancer. 2024; 24(1):1566.

PMID: 39710641 PMC: 11664856. DOI: 10.1186/s12885-024-13293-4.

Biological functions and molecular mechanisms of LINC01116 in cancer.

Shi K, Wang X, Huang L, Guo Q, Yuan W, Lv Y Heliyon. 2024; 10(21):e38490.

PMID: 39512466 PMC: 11539247. DOI: 10.1016/j.heliyon.2024.e38490.

LINC01116 affects patient survival differently and is dissimilarly expressed in ER+ and ER- breast cancer samples.

Karimi Taheri M, Ghanbari S, Gholipour A, Givi T, Sadeghizadeh M Cancer Rep (Hoboken). 2023; 6(8):e1848.

PMID: 37321964 PMC: 10432450. DOI: 10.1002/cnr2.1848.

References

Dang D, Makena M, Llongueras J, Prasad H, Ko M, Bandral M . A Ca-ATPase Regulates E-cadherin Biogenesis and Epithelial-Mesenchymal Transition in Breast Cancer Cells. Mol Cancer Res. 2019; 17(8):1735-1747. PMC: 6679749. DOI: 10.1158/1541-7786.MCR-19-0070. View

Brodie S, Lee H, Jiang W, Cazacu S, Xiang C, Poisson L . The novel long non-coding RNA TALNEC2, regulates tumor cell growth and the stemness and radiation response of glioma stem cells. Oncotarget. 2017; 8(19):31785-31801. PMC: 5458248. DOI: 10.18632/oncotarget.15991. View

Zubair M, Wang S, Ali N . Advanced Approaches to Breast Cancer Classification and Diagnosis. Front Pharmacol. 2021; 11:632079. PMC: 7952319. DOI: 10.3389/fphar.2020.632079. View

Liu P, Wang Z, Ou X, Wu P, Zhang Y, Wu S . The FUS/circEZH2/KLF5/ feedback loop contributes to CXCR4-induced liver metastasis of breast cancer by enhancing epithelial-mesenchymal transition. Mol Cancer. 2022; 21(1):198. PMC: 9555172. DOI: 10.1186/s12943-022-01653-2. View

Dall G, Hawthorne S, Seyed-Razavi Y, Vieusseux J, Wu W, Gustafsson J . Estrogen receptor subtypes dictate the proliferative nature of the mammary gland. J Endocrinol. 2018; 237(3):323-336. DOI: 10.1530/JOE-17-0582. View

Gruosso T, Mieulet V, Cardon M, Bourachot B, Kieffer Y, Devun F . Chronic oxidative stress promotes H2AX protein degradation and enhances chemosensitivity in breast cancer patients. EMBO Mol Med. 2016; 8(5):527-49. PMC: 5123617. DOI: 10.15252/emmm.201505891. View

Shang B, Li Z, Li M, Jiang S, Feng Z, Cao Z . Silencing LINC01116 suppresses the development of lung adenocarcinoma via the AKT signaling pathway. Thorac Cancer. 2021; 12(14):2093-2103. PMC: 8287011. DOI: 10.1111/1759-7714.14042. View

Zou Y, Ye F, Kong Y, Hu X, Deng X, Xie J . The Single-Cell Landscape of Intratumoral Heterogeneity and The Immunosuppressive Microenvironment in Liver and Brain Metastases of Breast Cancer. Adv Sci (Weinh). 2022; 10(5):e2203699. PMC: 9929130. DOI: 10.1002/advs.202203699. View

Shi Y, Zhao Y, Zhang Y, Aierken N, Shao N, Ye R . AFF3 upregulation mediates tamoxifen resistance in breast cancers. J Exp Clin Cancer Res. 2018; 37(1):254. PMC: 6192118. DOI: 10.1186/s13046-018-0928-7. View

10.

Bouris P, Skandalis S, Piperigkou Z, Afratis N, Karamanou K, Aletras A . Estrogen receptor alpha mediates epithelial to mesenchymal transition, expression of specific matrix effectors and functional properties of breast cancer cells. Matrix Biol. 2015; 43:42-60. DOI: 10.1016/j.matbio.2015.02.008. View

11.

Ren P, Chang L, Hong X, Xing L, Zhang H . Long non-coding RNA LINC01116 is activated by EGR1 and facilitates lung adenocarcinoma oncogenicity via targeting miR-744-5p/CDCA4 axis. Cancer Cell Int. 2021; 21(1):292. PMC: 8180037. DOI: 10.1186/s12935-021-01994-w. View

12.

Chen E, Tan C, Kou Y, Duan Q, Wang Z, Meirelles G . Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics. 2013; 14:128. PMC: 3637064. DOI: 10.1186/1471-2105-14-128. View

13.

Edgar R, Domrachev M, Lash A . Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2001; 30(1):207-10. PMC: 99122. DOI: 10.1093/nar/30.1.207. View

14.

Bashir M, Damineni S, Mukherjee G, Kondaiah P . Activin-A signaling promotes epithelial-mesenchymal transition, invasion, and metastatic growth of breast cancer. NPJ Breast Cancer. 2017; 1:15007. PMC: 5515205. DOI: 10.1038/npjbcancer.2015.7. View

15.

Zhao C, Lou Y, Wang Y, Wang D, Tang L, Gao X . A gene expression signature-based nomogram model in prediction of breast cancer bone metastases. Cancer Med. 2018; 8(1):200-208. PMC: 6346244. DOI: 10.1002/cam4.1932. View

16.

Guttilla I, Adams B, White B . ERα, microRNAs, and the epithelial-mesenchymal transition in breast cancer. Trends Endocrinol Metab. 2012; 23(2):73-82. DOI: 10.1016/j.tem.2011.12.001. View

17.

Hiscox S, Morgan L, Barrow D, Dutkowskil C, Wakeling A, Nicholson R . Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib ('Iressa', ZD1839). Clin Exp Metastasis. 2004; 21(3):201-12. DOI: 10.1023/b:clin.0000037697.76011.1d. View

18.

McAleese C, Choudhury C, Butcher N, Minchin R . Hypoxia-mediated drug resistance in breast cancers. Cancer Lett. 2020; 502:189-199. DOI: 10.1016/j.canlet.2020.11.045. View

19.

Wang W, Xin J, Chen W, Jing L, Zhang P . Icariin alleviates hypoxia-induced damage in MC3T3-E1 cells by downregulating TALNEC2. Biotechnol Appl Biochem. 2019; 67(6):1000-1010. DOI: 10.1002/bab.1874. View

20.

Chang P, Chen C, Yeh C, Lu H, Liu T, Chen M . Transcriptome analysis and prognosis of ALDH isoforms in human cancer. Sci Rep. 2018; 8(1):2713. PMC: 5807355. DOI: 10.1038/s41598-018-21123-4. View